New catheter lock solution could cut ICU infections

NCT ID NCT07366372

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a taurolidine-based lock solution can prevent infections in central venous catheters used in intensive care. 120 ICU patients received either the taurolidine solution, a tigecycline-heparin mix, or plain saline to lock their catheters. The goal was to see which approach best reduced bacterial growth and bloodstream infections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

taurolidine-citrate-heparin lock solution

What this could lead to

If effective, this could provide a simple way to reduce dangerous catheter infections in ICU patients, potentially saving lives and shortening hospital stays.

What could go wrong

This is a small, completed trial with 120 participants, so results may not apply to all ICU settings. The intervention also includes heparin and citrate, which carry bleeding or allergy risks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREVENTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Tanta University

    Tanta, El-Gharbia, 31527, Egypt